2017 Fiscal Year Final Research Report
Detection of blood biomarker in the patients' with Bevacizumab treated glioblastomas
| Project/Area Number |
16K20015
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Kuga Daisuke 九州大学, 医学研究院, 助教 (40759932)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | glioblastoma / liquid biopsy |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to predict the clinical course, efficacy of treatment in the patients with Bevacizumab treated glioblastoma analyzing the cell free DNA from tumor cell in the patients' blood. However, we were not able to detect any mutation of target gene in the patients' blood, indicating cell free DNA was not released into the blood. Then we used the patients' CSF as alternative candidate. We were able to some genes which originated from tumor cell in the patients' CSF. These results imply that CSF may be a good candidate for liquid biopsy in the patients with GBM.
|
| Free Research Field |
脳腫瘍
|
